NEW YORK (GenomeWeb News) – Bioheart, a Sunrise, Fla.-based developer of stem cell therapies for cardiovascular diseases, today said that it has entered into a global distribution and OEM pact for Life Technologies to sell the firm’s myoblast cell-based research products to life science researchers.

 

Bioheart said that the myoblast products will complement Life Technologies’ current portfolio of reagents for isolating, characterizing, expanding, and differentiating stem cells.